

Resource Summary Report

Generated by PRECISE-TBI on Sep 8, 2026

Proteon Therapeutics

RRID:SCR_004037

Type: Tool

Proper Citation

Proteon Therapeutics (RRID:SCR_004037)

Resource Information

URL: <http://www.proteontherapeutics.com/>

Proper Citation: Proteon Therapeutics (RRID:SCR_004037)

Description: A biopharmaceutical company developing pharmaceuticals for patients with renal and vascular diseases. Their ongoing Phase 3 clinical trial is evaluating whether a single treatment of PRT-201 can reduce vascular access failure, one of the most serious problems experienced by patients with chronic kidney disease (CKD) undergoing hemodialysis. PRT-201 is an investigational drug that may inhibit neointimal hyperplasia, the growth of tissue inside blood vessels that can result in vessel narrowing and reduced blood flow. PRT-201 has received fast track and orphan drug designations for hemodialysis vascular access indications. In September 2019, Proteon Therapeutics merged with ArTara Therapeutics.

Abbreviations: Proteon

Synonyms: Proteon Therapeutics Inc.

Resource Type: commercial organization

Keywords: biopharmaceutical, pharmaceutical, hemodialysis, prt-201, drug

Related Condition: Kidney disease, Vascular disease, Chronic kidney disease, Neointimal hyperplasia, Peripheral arterial disease

Resource Name: Proteon Therapeutics

Resource ID: SCR_004037

Alternate IDs: nlx_158465

Record Creation Time: 20220129T080222+0000

Record Last Update: 20260905T132513+0000

Ratings and Alerts

No rating or validation information has been found for Proteon Therapeutics.

No alerts have been found for Proteon Therapeutics.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Wen X, et al. (2016) A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV. PloS one, 11(5), e0155917.